.png "Global Insight")
For lakhs of Indian families, a cancer diagnosis brings two shocks: the medical one, and the bill. That second shock may be about to get smaller. India’s drug pricing regulator has approved capping trade margins on non-scheduled anti-cancer medicines at 30% of the maximum retail price — a move expected to cut prices by 20% to 70% and save patients around ₹2,500 crore every year. This article is general information only and is not medical advice.
What the NPPA Decided
At its meeting on October 8, chaired by Department of Pharmaceuticals Secretary Manoj Joshi, the National Pharmaceutical Pricing Authority approved in principle a proposal to cap the trade margin at 30% of MRP for identified non-scheduled anti-cancer drugs, under the Drugs (Prices Control) Order, 2013. The key distinction: the cap targets the margins of distributors, retailers and hospitals — not the price manufacturers charge. It is the middle of the supply chain, not the factory gate, that is being squeezed.
The Numbers Behind the Move
The figures the NPPA put on record are startling. Non-scheduled anti-cancer medicines carry an average trade mark-up of around 170% — and in some cases the mark-up reaches 700% or more. India’s anti-cancer drug market has an annual turnover of about ₹12,500 crore, most of it in non-scheduled drugs outside direct price control. With margins capped at 30%, the NPPA estimates retail prices of covered brands will fall broadly in the 20–70% range, depending on each medicine’s current mark-up, generating annual patient savings of roughly ₹2,500 crore.
Why Now: The Supreme Court’s Fury
The decision did not come from nowhere. Days earlier, the Supreme Court came down heavily on hospitals and the pharmaceutical industry over exorbitant cancer drug prices, with the bench describing the mark-ups as “broad daylight robbery.” The court questioned the vast gap between what retailers pay and what patients are charged. The NPPA has asked the Union Health Ministry to constitute an expert committee under the Directorate General of Health Services to recommend which medicines the cap will cover. The panel must submit its report by October 14, and reports suggest around 110 drugs — including 35 patented ones — could be included. The Supreme Court takes up the issue again on October 12.
What Happens Next — and the 2019 Precedent
This is not the first such exercise. In February 2019, the government capped trade margins on 42 non-scheduled anti-cancer medicines — and the results were dramatic: maximum retail prices fell by up to 91%, with reported annual savings of ₹984 crore across 526 brands, according to the government. The honest caveats: the current approval is “in principle,” and everything depends on the final drug list. Scheduled cancer drugs — the 63 covered under the National List of Essential Medicines — are already under ceiling-price control; this move extends the logic to the uncontrolled majority.
What It Means for Patients
If the list is broad and enforcement is real, this is one of the most significant affordability interventions in Indian healthcare in years. High out-of-pocket spending on cancer drugs pushes families into debt, forces asset sales, and sometimes stops treatment altogether. A 20–70% price cut does not cure cancer — but it can decide whether a family can afford to fight it. The margin cap also brings transparency: with trade margins published and capped, the days of 700% mark-ups hidden inside a hospital bill get harder to sustain. Watch the October 14 expert committee report. That list is where this story becomes real.
Follow Global Insight for daily explainers on health and science.